

**Product Name** : AK106-001616

**Synonyms** : AK 106-001616


**Cat No.** : M15184

**CAS Number** : 590416-75-4

**Molecular Formula** : C<sub>26</sub>H<sub>25</sub>N<sub>3</sub>O<sub>3</sub>

**Formula Weight** : 427.50

**Chemical Name** : 3-(3-amino-4-((2,3-dihydro-1H-inden-2-yl)oxy)-5-(1-methyl-1H-indazol-5-yl)phenyl)propanoic acid



**Description** : AK106-001616 (AK 106-001616) is a potent and selective inhibitor of cytosolic phospholipase A2 (cPLA2) with IC<sub>50</sub> of 3.8 nM (human cPLA2 enzyme); also inhibited rat cPLA2 with IC<sub>50</sub> of 4.3 nM, shows no significant activity against human iPLA2, bovine sPLA2 IB and PAF-AH (>10,000 fold selectivity); suppressed the release of AA from Ca<sup>2+</sup> ionophore A23187-stimulated rat RBL-2H3 cells (IC<sub>50</sub>=5.5 nM), also suppressed the production of PGE2 by LPS-stimulated human PBMCs (IC<sub>50</sub>=5.1 nM) and the production of LTB4 by Ca<sup>2+</sup> ionophore A23187-stimulated RBL-2H3 cells (IC<sub>50</sub>=2.6 nM); demonstrates in vivo efficacy for inflammation, neuropathic pain, and pulmonary fibrosis. Rheumatoid Arthritis Phase 2 Clinical

**Pathway** : Metabolic Enzyme/Protease

**Target** : Phospholipase

**Receptor** : Phospholipase

**Solubility** : —

**SMILES** : Cn1ncc2cc(ccc12)c3cc(CCC(=O)O)cc(N)c3OC4Cc5ccccc5C4

**Storage** : (-20°C)

**Stability** : ≥ 2 years

**Reference** :

1. Shimizu H, et al. J Pharmacol Exp Ther. 2019 Apr 10. pii: jpet.118.255034.